Exhibition Invitation | Hycells Biotechnology Invites You to Attend IBI EXPO 2023, the International Bio-Innovative Drug Industry Conference
Release Date:
2023-07-21 13:25
1. Company Overview
Shanghai Hycells Biotechnology Co., Ltd. was founded in 2021. With a team that has been deeply engaged in the fields of cell therapy and gene therapy for many years, the company is an innovative biotechnology firm primarily focused on providing products and services in these areas. The company’s core business is Human-derived immune cell collection, application services, and supporting solutions biological reagents The company has consistently built upon high-standard clinical sample collection and testing services, integrating biological sample analysis with translational medicine research to provide specialized in vitro and in vivo drug evaluation models and services for the development of innovative pharmaceuticals. The company adheres to Based on talent, quality first, and innovation as the foundation. Its core values are rooted in technological innovation, continuously enhancing the quality of clinical bio-sample collection, preparation, and application, setting new industry standards for domestic substitution, and providing a solid foundation for the development and global advancement of China’s innovative drugs.
Hycells Biotechnology continuously refines its quality management system and consistently updates and optimizes its technical service platform, adhering to Innovation, openness, and inclusiveness the corporate culture and attitude, based on Clinical needs and industry pain points By continuously innovating and introducing new offerings, we aim to deliver truly valuable, differentiated products and services to our customers. We look forward to, through our collective efforts, strengthening our R&D pipeline for innovative products and services, further empowering our industry partners, and jointly advancing the development of the cell therapy field.
2. Principal Business
One
Immune cells
Leukopaks
Peripheral Blood Mononuclear Cells
T/B/NK/Monocyte
Mobilized Leukopaks
Mobilized PBMC Cells
Mobilized CD34 Cells
Cord Blood Mononuclear Cells
Cord Blood CD34 Cells
Two
Immune Cell–Related Products
I. Cell Culture Media
NK Cell Expansion Culture Medium
DC cell culture medium
Macrophage cell culture medium
T-cell activation and expansion culture medium
Treg Cell Activation Culture Medium
γδ T cell expansion culture medium
II. Protein-Related Products
Cytokine
CAR positive rate detection reagent
Three
Immune Cell–Related Services
I. Verification of Specialized Sample Functions
1. Neutrophil-related tests
Separation and Purity Testing
Combined with experiments
Internalization Experiment
Reactive Oxygen Species Assay
Migration Experiment
Cytotoxicity assay
2. Whole blood/serum-related assays
Cytokine Release Assay
Antibody Stability Testing
II. Standard Pharmacodynamic Evaluation Protocol
Antibody-Dependent Cell Cytotoxicity Assay
Antibody-Dependent Cellular Phagocytosis Assay
Mixed Lymphocyte Reaction
Complement-dependent cytotoxicity
Cytokine Release Assay
III. Cell Activation, Expansion, and Induction Services (Featured Sample)
1. Specialized Cell Services
T-cell expansion
NK cell expansion
Treg cell induction and expansion
TH1/TH2/TH17 Induction Services
γδ T Cell Sorting and Expansion Service
2. Standard Specialty Cell Services
iDC/mDC induction services
M0/M1/M2 Induction Services
3. Irradiated PBMC Service
IV. Special Services
1. In vitro mRNA/peptide screening solution (customized service with guaranteed delivery timeline)
2. RLC Testing
3. Viral Neutralizing Antibody Testing
Related News
(II) Security Assurance Section | Safety First, Defense Prioritized
Compliance‑driven traceability establishes a clear “identity” for the product, but the real test lies in safety. While a multi‑donor pooling strategy ensures batch‑to‑batch consistency, it also inevitably elevates the risk of pathogen introduction. In the face of these associated risks and challenges, Heyousheng has never compromised on its manufacturing standards—relying on more precise design to deliver on its promise of enhanced safety.
This article will examine how He Yousheng proactively integrates the quality management system into the hospital setting, translating compliance requirements into concrete, actionable practices starting at the sample collection stage, thereby establishing a trust‑based chain that can withstand audit scrutiny.
In selecting hPL raw materials, Heyousheng consistently upholds the principle that “safety is determined at the source.” The samples used in production are rigorously collected in accordance with applicable standards and undergo stringent donor screening, effectively mitigating the risk of disease transmission at the very outset. Moreover, from informed consent forms and ethical approvals to clinical‑grade collection under the GCP framework, Heyousheng has established a fully traceable documentation chain, ensuring that every sample is accounted for and verifiable. In contrast to the industry’s longstanding reliance on the conventional model of using expired blood supplies from blood banks, this approach represents a structural, generational upgrade.
Recently, the research team led by Researcher Bian Yingjie at the Guangzhou National Laboratory, in collaboration with partners from Sun Yat-sen University, published a study titled “Iron overload in the tumor microenvironment induces CD8⁺ T cell ferroptosis and dysfunction” in the internationally renowned academic journal Nature Communications.
Hycells Recruitment | Never Stop Exploring, Never Stop Innovating
The company consistently upholds its core values of “people‑centricity, quality first, and innovation as the foundation,” remains driven by technological innovation, and sets new industry benchmarks for domestic innovation, thereby laying a solid foundation for the development and global advancement of China’s innovative pharmaceutical sector.
The HiXpan® NK Serum-Free Culture Kit, Version 3.0, is manufactured in strict compliance with GMP standards, and its production system fully adheres to relevant guidelines and regulations, including the “818 Requirements,” positioning it for pharmaceutical‑grade manufacturing and applications.
Contact Us
Phone: 021-36696819
Mobile phone:13061948224(Ms. Yu)
Email:monika@hys-bio.com
Wuxi Headquarters: 4th Floor, No. 15-1, Xianfeng Middle Road, Anzhen Subdistrict, Xishan District, Wuxi City
Shanghai Branch: Room 503, Building 2, No. 999 Jiangyue Road, Minhang District, Shanghai
Official Website
WeChat Official Account
Message Board